PD Guide
Adenosine-Based Approaches
The adenosine A2A receptor has received significant attention as a target for development of novel symptomatic therapies for PD. There is evidence that specific A2A antagonists reverse motor deficits and may alleviate dyskinesia in pre-clinical research models of PD (Xiao et al., 2006). Some pre-clinical research model studies suggest that A2A antagonists may also be neuroprotective (Schwarzchild et al., 2003). Several clinical trials have taken place using istradefylline, an A2A antagonist.
Reference:
Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli N, et al. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology. 2003;61(11 Suppl 6):S55-61.
Xiao D, Bastia E, Xu YH, Benn CL, Cha JH, Peterson TS, et al. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci. 2006;26(52):13548-55.
Responses:
Reference: